Physician profile
Sarah E Gerhardstein
NPI 1790026680
$2,347.49
in general payments reported to CMS, 2019-2025
26 companies · $78.45 in 2025
The $78.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $547 · 2021: $767 · 2022: $219 · 2025: $78.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $366.73 | 2019-2022 | |
| Abbvie INC. | $352.62 | 2019-2025 | |
| Amgen INC. | $258.74 | 2019-2021 | |
| Lilly USA, LLC | $225.06 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $216.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.77 | 2019-2022 | |
| Amarin Pharma, INC. | $88.45 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.58 | 2020-2021 | |
| Astellas Pharma US INC | $66.35 | 2019-2020 | |
| Pfizer INC. | $62.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $57.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.75 | 2019-2021 | |
| Eisai INC. | $35.82 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $31.62 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.36 | 2019 | |
| Shire North American Group INC | $20.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.16 | 2022 | |
| Abbott Laboratories | $18.23 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Glaxosmithkline, LLC. | $13.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2019 | |
| Mannkind Corporation | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gerhardstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.